| [1] |
Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology, 1983, 148(2): 397-401.
|
| [2] |
Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization[J]. Radiology, 1993, 188(1): 79-83.
|
| [3] |
Horikawa M, Miyayama S, Irie T, et al. Development of conventional transarterial chemoembolization for hepatocellular carcinomas in Japan: historical, strategic, and technical review[J]. AJR Am J Roentgenol, 2015, 205(4): 764-773.
|
| [4] |
Miyayama S, Matsui O, Taki K, et al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization[J]. Cardiovasc Intervent Radiol, 2006, 29(1): 39-48.
|
| [5] |
Miyayama S, Yamashiro M, Okuda M, et al. Anastomosis between the hepatic artery and the extrahepatic collateral or between extrahepatic collaterals: observation on angiography[J]. J Med Imaging Radiat Oncol, 2009, 53(3): 271-282.
|
| [6] |
Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome[J]. J Vasc Interv Radiol, 2016, 27(9): 1269-1278.
|
| [7] |
Golfieri R, Renzulli M, Mosconi C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? [J]. J Vasc Interv Radiol, 2013, 24(4): 509-517.
|
| [8] |
Yamakado K, Miyayama S, Hirota S, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? [J]. Jpn J Radiol, 2012, 30(7): 560-566.
|
| [9] |
李照，朱继业.《原发性肝癌诊疗规范（2017年版）》解读[J].临床肝胆病杂志，2017，33(9): 1655-1657.
|
| [10] |
Idee JM, Guiu B. Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review[J]. Crit Rev Oncol Hematol, 2013, 88(3): 530-549.
|
| [11] |
Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium[J]. Cancer, 1990, 66(9): 1897-1903.
|
| [12] |
Kan Z, Madoff DC. Liver anatomy: microcirculation of the liver[J]. Semin Intervent Radiol, 2008, 25(2): 77-85.
|
| [13] |
Kan Z. Dynamic study of iodized oil in the liver and blood supply to hepatic tumors. An experimental investigation in several animal species[J]. Acta Radiol Suppl, 1996, 408: 1-25.
|
| [14] |
Goseki N, Nosaka T, Endo M, et al. Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization[J]. Cancer, 1995, 76(5): 736-742.
|
| [15] |
Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil[J]. J Vasc Interv Radiol, 2007, 18(3): 365-376.
|
| [16] |
Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014, 111(2): 255-264.
|
| [17] |
Li Z, Ni RF, Busireddy KK, et al. Cerebral lipiodol embolism following transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of two cases and literature review[J]. Chin Med J（Engl）, 2011, 124(24): 4355-4358.
|
| [18] |
Nakao N, Uchida H, Kamino K, et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis[J]. Cardiovasc Intervent Radiol, 1994, 17(2): 76-80.
|
| [19] |
Tam KY, Leung KC, Wang YX. Chemoembolization agents for cancer treatment[J]. Eur J Pharm Sci, 2011, 44(1-2): 1-10.
|
| [20] |
de Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study[J]. Radiology, 1995, 194(1): 165-170.
|
| [21] |
Park C, Choi SI, Kim H, et al. Distribution of Lipiodol in hepatocellular carcinoma[J]. Liver, 1990, 10(2): 72-78.
|
| [22] |
Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cancer cells and endothelial cells incorporate iodised oil[J]. Br J Cancer, 1996, 73(7): 877-881.
|
| [23] |
Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012, 88(3): 53-71.
|
| [24] |
Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma[J]. Aliment Pharmacol Ther 2012, 35(11): 1343-1350.
|
| [25] |
Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies[J]. Cardiovasc Intervent Radiol, 2007, 30(1): 6-25.
|
| [26] |
Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency[J]. Cardiovasc Intervent Radiol, 2003, 26(2): 111-117.
|
| [27] |
Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis[J]. AJR Am J Roentgenol, 2010, 194(3): 830-837.
|
| [28] |
Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma[J]. Semin Intervent Radiol, 2013, 30(1): 3-11.
|
| [29] |
Jin B, Wang D, Lewandowski RJ, et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma[J]. AJR Am J Roentgenol, 2011, 196(4): 919-928.
|
| [30] |
施昌盛，杨庆，李成. Embosphere微球联合弹簧圈栓塞治疗大咯血的疗效分析[J/CD].中华介入放射学电子杂志, 2017, 5(4):269-272.
|
| [31] |
Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents[J]. J Vasc Interv Radiol, 2005, 16(12): 1661-1666.
|
| [32] |
Illum L, Davis SS. The targeting of drugs parenterally by use of microspheres[J]. J Parenter Sci Technol, 1982, 36(6): 242-248.
|
| [33] |
Bastian P, Bartkowski R, Kohler H, et al. Chemo-embolization of experimental liver metastases. Part I: distribution of biodegradable microspheres of different sizes in an animal model for the locoregional therapy[J]. Eur J Pharm Biopharm, 1998, 46(3): 243-254.
|
| [34] |
Lu W, Li Y, He X, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors[J]. Hepatogastroenterology, 2003, 50(54): 2079-2083.
|
| [35] |
Kan Z, Wright K, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models[J]. Acad Radiol, 1997, 4(4): 275-282.
|
| [36] |
El-Serag HB. Hepatocellular carcinoma[J]. N Engl J Med, 2011, 365(12): 1118-1127.
|
| [37] |
Tsochatzis EA, Fatourou E, O'Beirne J, et al. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(12): 3069-3077.
|
| [38] |
Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin（first cooperative study）. The Cooperative Study Group for Liver Cancer Treatment of Japan[J]. Cancer Chemother Pharmacol, 1992, 31(Suppl): S1-S6.
|
| [39] |
Chang JM, Tzeng WS, Pan HB, et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study[J]. Cancer, 1994, 74(9): 2449-2453.
|
| [40] |
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739.
|
| [41] |
Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2010, 33(3): 541-551.
|
| [42] |
Meyer T, Kirkwood A, Roughton M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs. embolisation alone for hepatocellular carcinoma[J]. Br J Cancer, 2013, 108(6): 1252-1259.
|
| [43] |
Tak E, Lee S, Lee J, et al. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells[J]. J Hepatol, 2011, 54(2): 328-339.
|
| [44] |
Facciorusso A, Licinio R, Muscatiello N, et al. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients[J]. World J Hepatol, 2015, 7(16): 2009-2019.
|
| [45] |
Ernst O, Sergent G, Mizrahi D, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response[J]. AJR Am J Roentgenol, 1999, 172(1): 59-64.
|
| [46] |
Yamashita Y, Torashima M, Oguni T, et al. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation[J]. Abdom Imaging, 1993, 18(4): 352-356.
|
| [47] |
Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update[J]. Oncology, 2014, 87(Suppl 1): 22-31.
|
| [48] |
Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology（JSH）2010 updated version[J]. Dig Dis, 2011, 29(3): 339-364.
|
| [49] |
Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Hepatology, 2013, 57(6): 2261-2273.
|
| [50] |
Adhoute X, Penaranda G, Naude S, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process[J]. J Hepatol, 2015, 62(4): 855-862.
|
| [51] |
Chen L, Ni CF, Chen SX, et al. A modified model for assessment for retreatment with transarterial chemoembolization in Chinese hepatocellular carcinoma patients[J]. J Vasc Interv Radiol, 2016, 27(9): 1288-1297.
|